Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility
Cosmos Health (NASDAQ:COSM) has announced that its subsidiary, Cana Laboratories, has secured a new 10-year contract manufacturing agreement with Provident Pharmaceuticals to produce four pharmaceutical products. The agreement covers the production of 8 million packs over the contract period, consisting of:
- Miorelique® (Baclofen oral solution): 200,000 packs annually
- BE Union F.C. (Vitamin B-complex tablets): 400,000 packs annually
- Certorun (Sertraline capsules) in 50mg and 100mg: 200,000 combined packs annually
Cana Laboratories currently operates with two shifts and has the capacity to expand to three shifts to meet increased demand. The products are generic versions of established medications Lioresal, Neurobion, and Zoloft, respectively.
Cosmos Health (NASDAQ:COSM) ha annunciato che la sua filiale, Cana Laboratories, ha stipulato un nuovo contratto di produzione della durata di 10 anni con Provident Pharmaceuticals per produrre quattro prodotti farmaceutici. L'accordo prevede la produzione di 8 milioni di confezioni nel periodo del contratto, suddivise in:
- Miorelique® (soluzione orale di Baclofen): 200.000 confezioni all'anno
- BE Union F.C. (compresse di complesso vitaminico B): 400.000 confezioni all'anno
- Certorun (capsule di Sertralina) da 50mg e 100mg: 200.000 confezioni complessive all'anno
Cana Laboratories attualmente opera con due turni e ha la capacità di espandere a tre turni per soddisfare la crescente domanda. I prodotti sono versioni generiche di farmaci consolidati come Lioresal, Neurobion e Zoloft, rispettivamente.
Cosmos Health (NASDAQ:COSM) ha anunciado que su subsidiaria, Cana Laboratories, ha asegurado un nuevo contrato de fabricación de 10 años con Provident Pharmaceuticals para producir cuatro productos farmacéuticos. El acuerdo abarca la producción de 8 millones de paquetes durante el periodo del contrato, que consiste en:
- Miorelique® (solución oral de Baclofeno): 200,000 paquetes anualmente
- BE Union F.C. (tabletas de complejo de vitamina B): 400,000 paquetes anualmente
- Certorun (cápsulas de Sertralina) en 50mg y 100mg: 200,000 paquetes combinados anualmente
Cana Laboratories actualmente opera con dos turnos y tiene la capacidad de expandirse a tres turnos para satisfacer la demanda creciente. Los productos son versiones genéricas de medicamentos establecidos como Lioresal, Neurobion y Zoloft, respectivamente.
코스모스 헬스 (NASDAQ:COSM)는 자회사인 카나 연구소(Cana Laboratories)가 프로비던트 제약(Provident Pharmaceuticals)과 10년 계약 제조 계약을 체결하고 네 가지 제약 제품을 생산하게 되었다고 발표했습니다. 이 계약은 계약 기간 동안 800만 개의 포장 제작을 포함합니다:
- 미올리크(Miorelique®) (바클로펜 경구 용액): 연간 200,000 포장
- BE 유니온 F.C. (비타민 B 복합체 정제): 연간 400,000 포장
- 세르트라제(Certorun) (세르트라린 캡슐) 50mg 및 100mg: 연간 총 200,000 포장
카나 연구소는 현재 두 교대 근무를 운영하고 있으며 수요 증가에 대응하기 위해 세 교대 근무로 확장할 수 있는 능력을 가지고 있습니다. 이 제품들은 각각 리오레살, 뉴로비온, 졸로프트의 일반 의약품입니다.
Cosmos Health (NASDAQ:COSM) a annoncé que sa filiale, Cana Laboratories, a obtenu un nouveau contrat de fabrication de 10 ans avec Provident Pharmaceuticals pour produire quatre produits pharmaceutiques. L'accord couvre la production de 8 millions de paquets durant la période du contrat, comprenant :
- Miorelique® (solution orale de baclofène) : 200 000 paquets par an
- BE Union F.C. (comprimés de complexe de vitamines B) : 400 000 paquets par an
- Certorun (capsules de sertraline) de 50 mg et 100 mg : 200 000 paquets combinés par an
Cana Laboratories fonctionne actuellement avec deux équipes et a la capacité d'étendre ses opérations à trois équipes pour répondre à la demande croissante. Les produits sont des versions génériques de médicaments bien établis tels que Lioresal, Neurobion et Zoloft.
Cosmos Health (NASDAQ:COSM) hat angekündigt, dass ihre Tochtergesellschaft Cana Laboratories einen neuen 10-Jahres-Vertrag über die Vertragsfertigung mit Provident Pharmaceuticals zur Herstellung von vier pharmazeutischen Produkten gesichert hat. Der Vertrag umfasst die Produktion von 8 Millionen Packungen über die Vertragslaufzeit, bestehend aus:
- Miorelique® (Baclofen-oral Lösung): 200.000 Packungen jährlich
- BE Union F.C. (Vitamin-B-Komplex-Tabletten): 400.000 Packungen jährlich
- Certorun (Sertralin-Kapseln) in 50mg und 100mg: 200.000 kombinierte Packungen jährlich
Cana Laboratories betreibt derzeit mit zwei Schichten und hat die Kapazität, auf drei Schichten zu erweitern, um der gestiegenen Nachfrage gerecht zu werden. Die Produkte sind generische Versionen von etablierten Arzneimitteln wie Lioresal, Neurobion und Zoloft.
- Secured long-term 10-year manufacturing contract providing stable revenue visibility
- High-margin contract manufacturing expansion with 8 million total packs
- Production capacity can be increased with addition of third shift
- Diversified product portfolio with both pharmaceutical and supplement products
- None.
Insights
This 10-year manufacturing agreement marks a strategic milestone for Cosmos Health, significantly strengthening its contract manufacturing division. The deal's structure offers several key advantages:
The production portfolio is well-diversified across different therapeutic areas: muscle relaxants (Miorelique®), vitamins (BE Union F.C.) and mental health medications (Certorun). This mix provides natural hedging against market fluctuations in any single therapeutic category.
The production volumes are particularly noteworthy: 800,000 packs annually represents a substantial base load for Cana's manufacturing facilities. This steady production schedule allows for optimal capacity utilization and improved operational efficiency. The current two-shift operation with potential expansion to three shifts indicates significant manufacturing flexibility and scalability.
From a financial perspective, contract manufacturing typically generates margins between 30-40% in the pharmaceutical industry. The 10-year duration provides exceptional revenue visibility and stable cash flows, which are particularly valuable for a company of Cosmos's size. This long-term commitment also strengthens Cosmos's position when seeking financing or additional contracts.
The agreement to manufacture generic versions of established drugs like Zoloft and Lioresal is strategically sound, as these medications have proven market demand and well-understood safety profiles. This reduces commercial risk while maintaining steady production volumes.
The deal reinforces Cana's position as a reliable contract manufacturer and could attract similar long-term agreements from other pharmaceutical companies. For a company with a market cap of
CHICAGO, IL / ACCESS Newswire / February 7, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly owned subsidiary, Cana Laboratories ("Cana"), has entered into a new long-term ten-year contract manufacturing agreement with Provident Pharmaceuticals ("Provident"), a specialty pharmaceutical company, to produce four pharmaceutical products. These include Miorelique®, BE Union F.C., and two variations of Certorun, with a total production volume of 800,000 packs per year, or 8,000,000 packs over the ten-year period.
Details of the Agreement
The agreement covers the production of Miorelique®, an oral solution containing the active ingredient Baclofen, with an annual production volume of 200,000 packs. This product follows Lioresal as the reference drug, a well-established muscle relaxant used to treat spasticity.
It also includes the production of BE Union F.C. tablets, formulated with Thiamine, Pyridoxine, and Cyanocobalamin, with an annual production volume of 400,000 packs. These tablets are developed with Neurobion as the reference drug, a vitamin B-complex supplement commonly used for neuropathy and nerve health support.
Additionally, the agreement covers the production of Certorun capsules, available in 50 mg and 100 mg formulations, containing the active ingredient Sertraline, with a combined annual production volume of 200,000 packs. This product follows Zoloft as the reference drug, an antidepressant widely prescribed for mood and anxiety disorders.
Greg Siokas, CEO of Cosmos Health, stated: "We are very pleased to expand our already successful collaboration with Provident, further accelerating the growth of our contract manufacturing business at Cana's state-of-the-art facilities. These additional orders from Provident underscore our capabilities, and we remain well-positioned to accommodate further contract manufacturing opportunities that contribute to stable, long-term, high-margin cash flows for Cosmos. Cana is currently operating with two shifts and has the ability to expand to three shifts, enabling the Company to operate around the clock to meet increased demand."
About Provident Pharmaceuticals
Provident, established in 2012, is a privately held specialty pharmaceutical company focused on commercializing and marketing niche and legacy pharmaceutical products and medical devices. Operating in both private and public sectors in Greece, it ensures high-quality, therapeutically valuable products, adhering to European standards. Provident offers comprehensive services, including sales, marketing, regulatory support, market access, and distribution. As market leaders in muscle spasticity and strong performers in HA for joints, oncology, and alimentary tract/metabolism, its mission is to provide innovative, high-quality medicines. The product portfolio spans cardiovascular, central nervous system, oncology, vitamins, medical devices, and veterinary products.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
What is the total production volume of the new COSM manufacturing contract with Provident?
Which products will COSM manufacture under the new Provident contract?
What is the annual production volume for BE Union F.C. under COSM's new contract?
How many shifts is Cana Laboratories currently operating under COSM?
What are the reference drugs for COSM's new contract products?
